Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AqT-DM1
- Development stage
- Preclinical
- Lead developer
- AqueaTether Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AqT-DM1 is a proprietary antibody-drug conjugate (ADC) payload developed by AqueaTether Therapeutics, a subsidiary of CellMosaic. It consists of the potent microtubule-disrupting agent DM1 (mertansine), a maytansinoid derivative, which is conjugated to the AqueaTether (AqT) platform technology. The AqT technology utilizes a highly hydrophilic, non-immunogenic tether designed to improve the aqueous solubility of hydrophobic payloads like DM1, thereby enhancing conjugation efficiency and the pharmacokinetic properties of the resulting ADC. DM1 exerts its cytotoxic effect by binding to tubulin, which inhibits microtubule polymerization and leads to cell cycle arrest in mitosis followed by apoptosis. AqT-DM1 is intended for use as a platform asset in the development of targeted therapies for various types of cancer.
- Other names
- AqueaTether-DM1AqueaTether-DM-1AqueaTether-DM 1maytansinoid DM1mertansine-AqueaTether
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AqT-DM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AqT-DM1.